Responsive image

Free Access to Our
Online Perfusion

Registration is free and all content is free to watch.
Payment is only required if you choose to earn CEU through us.


Mediweb logo
Perfweb logo
Nurseweb logo

David Platt, Ph.D

Dr. David Platt has a PhD in carbohydrate chemistry from the Weizmann Institute of Science in Israel and completed his post-doctoral work at Wayne State University in Michigan. He is a pioneer in designing drugs derived from co-polymers. He has over 30 years of experience in drug development, with over 30 patents, authored 10 journal articles, completed 2 textbooks, CEO of 5 public companies, 3 of which were NASDAQ, and conducted over 30 clinical trials. He was the very first to combine chemotherapy with a co-polymer to target cancer which radically improved the safety profile of the treatments. He coined the name Galectin and was the first to publish in a field of research that now produces over 300 peer reviewed articles annually. His life’s work is embodied in his latest invention called BXT-25 which is an oxygen transport delivery drug that is 5000 times smaller than a red blood cell and is capable of treating stroke, ARDS, and other diseases that have an element of hypoxia within the disease.